Related Research Articles
Colorectal cancer (CRC),also known as bowel cancer,colon cancer,or rectal cancer,is the development of cancer from the colon or rectum. Signs and symptoms may include blood in the stool,a change in bowel movements,weight loss,and fatigue. Most colorectal cancers are due to old age and lifestyle factors,with only a small number of cases due to underlying genetic disorders. Risk factors include diet,obesity,smoking,and lack of physical activity. Dietary factors that increase the risk include red meat,processed meat,and alcohol. Another risk factor is inflammatory bowel disease,which includes Crohn's disease and ulcerative colitis. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer;however,these represent less than 5% of cases. It typically starts as a benign tumor,often in the form of a polyp,which over time becomes cancerous.
The Leukemia &Lymphoma Society (LLS),a 501(c)(3) charitable organization founded in 1949,is the largest voluntary health organization dedicated to fighting blood cancer in the world. The LLS's mission is to cure leukemia,lymphoma,Hodgkin's lymphoma and myeloma,and improve the quality of life of patients and their families.
Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo,New York. Founded by surgeon Roswell Park in 1898,the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center,which conducts clinical research on cancer as well as the development new drugs,provides advanced treatment for all forms of adult and pediatric cancer,and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019,the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".
A cancer survivor is a person with cancer of any type who is still living. Whether a person becomes a survivor at the time of diagnosis or after completing treatment,whether people who are actively dying are considered survivors,and whether healthy friends and family members of the cancer patient are also considered survivors,varies from group to group. Some people who have been diagnosed with cancer reject the term survivor or disagree with some definitions of it.
Lapatinib (INN),used in the form of lapatinib ditosylate (USAN) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops,conducts,coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches,and the testing of more effective therapeutic strategies,using currently approved drugs,surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Zbtb7,whose protein product is also known as Pokemon,is a gene that functions as a regulator of cellular growth and a proto oncogene.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
Carol E. Cass is a Canadian research scientist. From 2003 to 2010,Cass served as director of Alberta's Cross Cancer Institute. She is Canada Research Chair in oncology at the University of Alberta and was elected a Fellow of the Royal Society of Canada and Canadian Academy of Health Sciences.
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
Oncology is a branch of medicine that deals with the study,treatment,diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος(ónkos),meaning "tumor","volume" or "mass". Oncology is concerned with:
Cross Cancer Institute is the comprehensive cancer centre for northern Alberta. The institute,named for Wallace Warren Cross,is located in Edmonton near the southwest corner of the University of Alberta,and is one of two tertiary cancer centres in the province. The Cross Cancer Institute is a lead centre for the province-wide prevention,research and treatment program. The centre provides inpatient and outpatient services for cancer patients,advanced medical and supportive cancer care,and patient and professional education. The Cross Cancer Institute conducts research through the Alberta Cancer Research Institute.
Cancer can be treated by surgery,chemotherapy,radiation therapy,hormonal therapy,targeted therapy and synthetic lethality,most commonly as a series of separate treatments. The choice of therapy depends upon the location and grade of the tumor and the stage of the disease,as well as the general state of the patient. Cancer genome sequencing helps in determining which cancer the patient exactly has for determining the best therapy for the cancer. A number of experimental cancer treatments are also under development. Under current estimates,two in five people will have cancer at some point in their lifetime.
High-dose chemotherapy and bone marrow transplant (HDC/BMT),also high-dose chemotherapy with autologous bone marrow transplant,was an ineffective treatment regimen for metastatic breast cancer,and later high-risk breast cancer,that was considered promising during the 1980s and 1990s. With an overall idea that more is better,this process involved taking cells from the person's bone marrow to store in a lab,then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed,and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment,and to have significantly higher side effects,including treatment-related death.
Richard Margolese,MD,CM FRCS (C),is a Canadian scientist and has been a leader of multiple research studies that have changed the standard treatment for early-stage breast cancer. He is a native of Montreal,Canada.
Kathleen I. Pritchard,is the head of oncology at Sunnybrook Health Sciences Centre in Toronto,Canada,specializing in breast cancer therapies,and leading the clinical trials division of the centre. She has authored numerous studies on women's health,breast cancer,hormone replacement therapy,public health,and research methodology. According to Thomson Reuters,Pritchard was one of the most cited researchers in the world in 2014 and 2015.
Abemaciclib,sold under the brand name Verzenio among others,is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Carole Anne Estabrooks is a Canadian applied health services researcher. She is a Canada Research Chair in Knowledge Translation and a professor in the Faculty of Nursing at the University of Alberta. She has been listed amongst the highest cited researchers in her field and was appointed a Member of the Order of Canada in 2016.
G1 Therapeutics,Inc. is an American biopharmaceutical company headquartered in Research Triangle Park,North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.
Bisantrene,trademarked as Zantrène,is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity and an antimetabolite. Bisantrene intercalates with and disrupts the configuration of DNA,resulting in DNA single-strand breaks,DNA-protein crosslinking,and inhibition of DNA replication. This agent is similar to doxorubicin in activity,but unlike anthracyclines like doxorubicin,exhibits little cardiotoxicity.
References
- ↑ "Courneya, Kerry Stephen, 1963-". viaf.org. Retrieved April 11, 2021.
- ↑ "Kerry Courneya, PhD". apps.ualberta.ca. Retrieved April 12, 2021.
- ↑ "Kerry Courneya". publichealth.yale.edu. Retrieved May 17, 2021.
- ↑ Struzik, Ed (June 3, 1999). "Doctor prescribes rough therapy for cancer patients". Calgary Herald. Retrieved May 17, 2021– via newspapers.com.
- ↑ "Kerry Courneya - 2012". mcgill.ca. Retrieved May 17, 2021.
- ↑ "Exercise Is Good Medicine For Lymphoma Patients". sciencedaily.com. Science Daily. November 7, 2009. Retrieved May 17, 2021.
- ↑ "CARE Trial to blaze new trail for exercise during cancer treatment". ualberta.ca. April 17, 2007. Retrieved May 17, 2021.
- 1 2 "Canada Research Chair renewal for Kerry Courneya". eurekalert.org. Eurekalert. October 25, 2011. Retrieved May 17, 2021.
- ↑ Courneya, K. S.; Booth, C. M.; Gill, S.; O'Brien, P.; Vardy, J.; Friedenreich, C. M.; Au, H. J.; Brundage, M. D.; Tu, D.; Dhillon, H.; Meyer, R. M. (December 2008). "The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group". Current Oncology . 15 (6): 279–285. doi:10.3747/co.v15i6.378. PMC 2601017 . PMID 19079628.
- ↑ Hurly, Jane (July 27, 2010). "CIHR team grant to fund wide-ranging research into physical activity and breast cancer survivorship". ualberta.ca. Retrieved May 17, 2021.
- ↑ Hurly, Jane (May 2, 2012). "National award for cancer researcher". ualberta.ca. Retrieved May 17, 2021.
- ↑ Courneya, Kerry S.; Vallance, Jeff K.; Culos-Reed, S Nicole; McNeely, Margaret L.; Bell, Gordon J.; MacKey, John R.; Yasui, Yutaka; Yuan, Yan; Matthews, Charles E.; Lau, David CW; Cook, Diane; Friedenreich, Christine M. (November 16, 2012). "The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors". BMC Cancer. 12. doi: 10.1186/1471-2407-12-525 .
- ↑ Graham, Nicole (November 13, 2018). "Courneya renewed as Tier I Canada Research Chair in Physical Activity and Cancer". ualberta.ca. Retrieved May 17, 2021.
- ↑ Soke, Shelby (August 7, 2018). "UAlberta professors recognized for excellence in supportive and palliative oncology". ualberta.ca. Retrieved May 17, 2021.
- ↑ "Kerry S. Courneya named winner of the 2019 Manulife Prize". reporter.mcgill.ca. April 1, 2019. Retrieved May 17, 2021.
- ↑ "Awards for excellence in cancer research". torontoriot.com. 2019. Retrieved May 17, 2021.
- ↑ "Order of Canada appointees – June 2023". The Governor General of Canada. June 30, 2023. Retrieved June 30, 2023.
